Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Shares Issued (2016 - 2025)

Ocular Therapeutix has reported Shares Issued over the past 13 years, most recently at -$73.5 million for Q4 2025.

  • Quarterly results put Shares Issued at -$73.5 million for Q4 2025, up 76.7% from a year ago — trailing twelve months through Dec 2025 was $118.8 million (up 11588.19% YoY), and the annual figure for FY2025 was $20.5 million, up 1922.05%.
  • Shares Issued for Q4 2025 was -$73.5 million at Ocular Therapeutix, down from $94.0 million in the prior quarter.
  • Over the last five years, Shares Issued for OCUL hit a ceiling of $315.9 million in Q3 2024 and a floor of -$315.3 million in Q4 2024.
  • Median Shares Issued over the past 5 years was $426000.0 (2022), compared with a mean of $7.0 million.
  • Biggest five-year swings in Shares Issued: skyrocketed 80118.18% in 2023 and later tumbled 102482.14% in 2024.
  • Ocular Therapeutix's Shares Issued stood at $2.1 million in 2021, then plummeted by 79.68% to $426000.0 in 2022, then dropped by 27.7% to $308000.0 in 2023, then tumbled by 102482.14% to -$315.3 million in 2024, then soared by 76.7% to -$73.5 million in 2025.
  • The last three reported values for Shares Issued were -$73.5 million (Q4 2025), $94.0 million (Q3 2025), and $94.0 million (Q2 2025) per Business Quant data.